Millions with peripheral artery disease not getting vital medications

June 20, 2011, American Heart Association

Millions of adults with peripheral artery disease are not receiving the medications needed to reduce their risk of heart attack, stroke and death, according to research in Circulation: Journal of the American Heart Association.

Most patients are not receiving recommended therapies such as cholesterol and blood pressure-lowering medications, the study's authors found. Peripheral artery disease is the result of , or in the arteries in the legs caused by plaque. People with this disease have a significantly increased risk of having either a non-fatal or fatal heart attack or stroke because atherosclerosis can also affect the arteries supplying blood to the heart and brain.

Of the estimated 7.1 million U.S. adults with , also known as PAD, the study found:

  • Two in three, or about 5 million, are not taking cholesterol-lowering medications.
  • Nearly three in four, or about 5.4 million, are not receiving angiotensin converting enzyme inhibitors or angiotensin receptor blockers, which are blood pressure-lowering medications.
  • Two in three, or about 4.5 million, are not taking aspirin, which may reduce the .
"We found that taking two or more of these medications was associated with a 65 percent lower rate of death from all causes," said Reena L. Pande, M.D., study lead author and an instructor at the Harvard Medical School in Boston. "The study tells us that millions of individuals identified with PAD by a simple non-invasive screening test are not receiving medications that may reduce their risk of death."

The most common symptom of PAD is a painful muscle cramping in the hips, thighs or calves when walking, climbing stairs or exercising. This can be treated with medications, or restoring blood flow by surgical . The increased risk of fatal or non-fatal heart attacks and strokes for individuals with PAD can be modified by using medications, such as statins and aspirin, said Pande who is also an associate physician in the cardiovascular division of Brigham and Women's Hospital in Boston.

In this study, researchers used a simple screening test – ankle brachial index – to identify whether people who have PAD, but no known heart disease, would benefit from medications to reduce the risk of cardiovascular events.

The ankle brachial index is a comparison between the blood pressure in an individual's arm and the blood pressure in their ankle. A low number indicates that the arteries in the legs might be narrowed, which impedes blood flow and can indicate a high risk of heart disease and stroke.

Researchers studied data from 7,458 adults from 1999 to 2004, using the National Health and Nutrition Examination Survey, to determine how many of these asymptomatic individuals were not taking medications to lower their risk of and stroke, and whether taking these medications resulted in lower death rates.

The data used for this analysis did not provide information that would explain the reasons why these patients were not receiving the risk lowering therapies, but the study suggests that identification of PAD using ABI test screening might make physicians aware of the diagnosis of PAD and make them more likely to prescribe these medications.

Pande noted that these findings are observational, which means the researchers analyzed existing data. The conclusions from this study need to be repeated in larger trials that are designed specifically to validate these results, before scientists and physicians can begin to examine how best to address the issue of providing risk lowering treatments for asymptomatic patients with PAD.

Related Stories

Recommended for you

Researchers borrow from AIDS playbook to tackle rheumatic heart disease

January 22, 2018
Billions of US taxpayer dollars have been invested in Africa over the past 15 years to improve care for millions suffering from the HIV/AIDS epidemic; yet health systems on the continent continue to struggle. What if the ...

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jun 20, 2011
Sounds like an advertisement by PhRMA from their agent, the AHA, to sell more more money making drugs. After almost 60 yrs of cholesterol being being labeled a bad actor, and $100's of Billions in drug sales, there is still little real research data showing that lowering cholesterol does anything to prolong the life of the patient.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.